Vertex Pharmaceuticals (VRTX) 주식 개요
버텍스 파마슈티컬스는 미국, 유럽 및 국제적으로 생명공학 회사로 운영되고 있습니다. 자세히 보기
강점
위험 분석
VRTX가 우리의 위험 점검을 통과했습니다.
VRTX Community Fair Values
Create NarrativeSee what 236 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
Vertex Pharmaceuticals Incorporated 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$429.82 |
| 52주 최고가 | US$507.92 |
| 52주 최저가 | US$362.50 |
| 베타 | 0.30 |
| 1개월 변동 | -1.48% |
| 3개월 변동 | -7.26% |
| 1년 변동 | -2.17% |
| 3년 변동 | 23.28% |
| 5년 변동 | 98.67% |
| IPO 이후 변동 | 9,451.56% |
최근 뉴스 및 업데이트
Seeking Alpha • May 06
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy
Summary Vertex Pharmaceuticals Incorporated delivered strong Q1 2026 earnings, with $2.99bn revenue and $4.02 EPS, but revenue growth is slowing as CF market saturates. VRTX's cystic fibrosis franchise remains dominant and highly profitable, but diversification efforts—Casgevy, Journavx, and povetacicept—face slow uptake or intense competition. Forward P/E of ~26.5x and P/S of ~8.3x are above Big Pharma averages, reflecting market concerns about future growth for VRTX beyond CF. I maintain a Hold rating on VRTX stock, as reigniting share price momentum likely requires bold M&A or accelerated pipeline success, given limited near-term diversification impact. Read the full article on Seeking Alpha
내러티브 업데이트 • May 05
VRTX: CF Base And Nephrology Expansion Will Define Balanced Future Risk Profile
Analysts have inched their average price target for Vertex Pharmaceuticals higher by a few dollars, citing stronger confidence in povetacicept after positive Phase 3 RAINIER data in IgA nephropathy and a broader nephrology pipeline thesis, while keeping valuation assumptions such as P/E and discount rate broadly consistent. Analyst Commentary Recent Street research on Vertex Pharmaceuticals has centered on povetacicept and the nephrology pipeline, with several major firms adjusting their models after the Phase 3 RAINIER interim readout in IgA nephropathy and following Q4 results.내러티브 업데이트 • Apr 20
VRTX: CF Franchise And Kidney Pipeline Will Shape Balanced Risk Profile
Vertex Pharmaceuticals' fair value estimate has shifted from $403.80 to $412.49 as analysts refresh models following multiple price target increases tied to positive Phase 3 povetacicept data and a reassessment of the company's nephrology pipeline potential. Analyst Commentary Recent Street research on Vertex Pharmaceuticals has leaned constructive overall, with several firms lifting price targets following the Phase 3 RAINIER interim readout for povetacicept and updating models around the nephrology pipeline.Recent updates
Seeking Alpha • May 06
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy
Summary Vertex Pharmaceuticals Incorporated delivered strong Q1 2026 earnings, with $2.99bn revenue and $4.02 EPS, but revenue growth is slowing as CF market saturates. VRTX's cystic fibrosis franchise remains dominant and highly profitable, but diversification efforts—Casgevy, Journavx, and povetacicept—face slow uptake or intense competition. Forward P/E of ~26.5x and P/S of ~8.3x are above Big Pharma averages, reflecting market concerns about future growth for VRTX beyond CF. I maintain a Hold rating on VRTX stock, as reigniting share price momentum likely requires bold M&A or accelerated pipeline success, given limited near-term diversification impact. Read the full article on Seeking Alpha내러티브 업데이트 • May 05
VRTX: CF Base And Nephrology Expansion Will Define Balanced Future Risk Profile
Analysts have inched their average price target for Vertex Pharmaceuticals higher by a few dollars, citing stronger confidence in povetacicept after positive Phase 3 RAINIER data in IgA nephropathy and a broader nephrology pipeline thesis, while keeping valuation assumptions such as P/E and discount rate broadly consistent. Analyst Commentary Recent Street research on Vertex Pharmaceuticals has centered on povetacicept and the nephrology pipeline, with several major firms adjusting their models after the Phase 3 RAINIER interim readout in IgA nephropathy and following Q4 results.내러티브 업데이트 • Apr 20
VRTX: CF Franchise And Kidney Pipeline Will Shape Balanced Risk Profile
Vertex Pharmaceuticals' fair value estimate has shifted from $403.80 to $412.49 as analysts refresh models following multiple price target increases tied to positive Phase 3 povetacicept data and a reassessment of the company's nephrology pipeline potential. Analyst Commentary Recent Street research on Vertex Pharmaceuticals has leaned constructive overall, with several firms lifting price targets following the Phase 3 RAINIER interim readout for povetacicept and updating models around the nephrology pipeline.
내러티브 업데이트 • Apr 05
VRTX: Renal Franchise Progress And CF Leadership Will Drive Future Upside
Vertex Pharmaceuticals' analyst fair value estimate has shifted to $641 from $604. This reflects analysts' updated views on the company's diversified pipeline following positive Phase 3 povetacicept data in IgA nephropathy and a series of higher Street price targets.
내러티브 업데이트 • Mar 22
VRTX: Renal Trial Success And Nephrology Pipeline Will Drive Next Phase
Vertex Pharmaceuticals' analyst fair value estimate has moved from $504.04 to $547.72. Analysts point to higher modeled revenue growth, slightly stronger profit margins, a richer future P/E assumption, and a wave of Street price target hikes tied to positive povetacicept Phase 3 RAINIER data and the growing nephrology pipeline.내러티브 업데이트 • Mar 06
VRTX: CF Dependence Will Heighten Risk Around Upcoming Renal Readouts
Analysts have nudged their target on Vertex Pharmaceuticals higher, with our fair value estimate moving from $401.30 to $403.80. This reflects updated Q4 results, slightly adjusted revenue growth and margin assumptions, and ongoing confidence in the broader pipeline, as seen in a series of recent price target increases across the Street.
새 내러티브 • Feb 27
Vertex Pharmaceuticals (VRTX): The Diversification Juggernaut – Beyond the CF Monopoly
Vertex Pharmaceuticals (VRTX) has entered a transformative era where its identity is shifting from a "Cystic Fibrosis (CF) company" to a multi-disease powerhouse. Following its Q4 fiscal 2025 earnings report on February 12, 2026 , the stock demonstrated resilience, trading at $495.43 as of February 27.내러티브 업데이트 • Feb 20
VRTX: CF Reliance Will Expose Renal Pipeline Execution Risks
Vertex Pharmaceuticals' updated analyst price target reflects an increase of $23.78 to $401.30, as analysts incorporate refreshed Q4 outcomes, pipeline commentary on programs like povetacicept and IgAN, and modest adjustments to assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Street research around Vertex Pharmaceuticals has been active following the latest Q4 update, with several firms revisiting their models, refreshing pipeline assumptions, and revising price targets.내러티브 업데이트 • Feb 06
VRTX: CF Dependence And Pipeline Execution Risks Will Test Bullish Repricing
Analysts have raised their fair value estimate for Vertex Pharmaceuticals by about US$33 to approximately US$378, citing a series of recent rating upgrades and higher price targets linked to its cystic fibrosis franchise and late-stage pipeline potential. Analyst Commentary Recent research on Vertex Pharmaceuticals has been dominated by upgrades and higher price targets, with several firms shifting to more positive ratings and highlighting the cystic fibrosis portfolio and late stage pipeline as key supports for the updated fair value assessments.내러티브 업데이트 • Jan 23
VRTX: CF Cash Flows And Renal Data Will Shape Balanced Next Phase
Analysts have nudged their fair value estimate for Vertex Pharmaceuticals higher to about $504, citing a slightly richer assumed future P/E multiple and modestly stronger revenue growth expectations, even as they factor in a lower profit margin and a slightly higher discount rate. Analyst Commentary Recent Street research on Vertex Pharmaceuticals has turned more constructive, with several firms shifting to more positive ratings and setting price targets above the current fair value estimate.내러티브 업데이트 • Jan 09
VRTX: CF Durability And Kidney Pipeline Data Will Define Next Phase
Analysts have lifted their Vertex Pharmaceuticals fair value estimate by about US$11 to US$496.16, reflecting updated assumptions on revenue growth, margins and future P/E, as recent research highlights confidence in the durability of its cystic fibrosis franchise and potential upside from its broader pipeline. Analyst Commentary Recent Street research around Vertex Pharmaceuticals points to a generally constructive view, with most commentary focusing on the durability of the cystic fibrosis franchise, the breadth of the pipeline and how these factors feed into valuation targets and rating changes.내러티브 업데이트 • Dec 18
VRTX: Cystic Fibrosis And Gene Editing Advances Will Drive Upside Potential
Narrative Update The analyst price target for Vertex Pharmaceuticals has been modestly reduced to about $604 from roughly $616 as analysts factor in a slightly higher discount rate and marginally slower revenue growth, partially offset by improved profitability and a lower assumed future P/E multiple. Analyst Commentary Bullish analysts remain broadly constructive on Vertex Pharmaceuticals, emphasizing durable execution in cystic fibrosis, a deep late stage pipeline, and multiple emerging revenue drivers that, in their view, support premium valuation multiples despite modest target tweaks.내러티브 업데이트 • Dec 04
VRTX: Kidney Pipeline And Gene Editing Will Shape Next Phase
The analyst price target for Vertex Pharmaceuticals has been nudged higher to about $485 from roughly $480 as analysts point to a healthier long term earnings profile supported by ongoing strength in the cystic fibrosis franchise, measured diversification investments, and an increasingly innovation focused large cap biopharma setup. Analyst Commentary Recent research updates on Vertex Pharmaceuticals highlight a broadly constructive stance on the name, with most price target changes and rating initiations reinforcing confidence in the company’s growth algorithm and innovation pipeline, even as some voices flag valuation and execution constraints as the franchise matures.분석 기사 • Nov 11
Vertex Pharmaceuticals' (NASDAQ:VRTX) Performance Is Even Better Than Its Earnings Suggest
Even though Vertex Pharmaceuticals Incorporated's ( NASDAQ:VRTX ) recent earnings release was robust, the market didn't...분석 기사 • Sep 19
Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Popularity With Investors Is Under Threat From Overpricing
It's not a stretch to say that Vertex Pharmaceuticals Incorporated's ( NASDAQ:VRTX ) price-to-sales (or "P/S") ratio of...내러티브 업데이트 • Sep 04
Gene Editing And New Therapies Will Transform Global Healthcare
Analysts maintain a cautious-but-constructive stance on Vertex Pharmaceuticals, citing strong CF performance and resilient topline results offset by pipeline setbacks and future revenue concentration risks, with the consensus price target unchanged at $481.04. Analyst Commentary Bullish analysts highlight Vertex’s continued strong execution track record, robust base cystic fibrosis (CF) business, solid Q2 results with topline beats, and a positive long-term growth outlook beyond near-term setbacks.새 내러티브 • Apr 08
New ALYFTREK And JOURNAVX Will Expand Patient Access
Vertex is set to drive revenue growth by expanding its drug portfolio, notably with ALYFTREK and JOURNAVX, targeting new patient demographics.Seeking Alpha • Apr 06
Vertex Pharmaceuticals: A Look At Their Pain Therapy Program
Summary Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain, sickle cell disease, beta thalassemia, and type 1 diabetes, with approved products in each area. Suzetrigine (Journavx) shows promise as a non-addictive pain treatment, offering systemic relief without opioid-related side effects, but faces Tier 3 insurance hurdles. Financially strong with a market cap of $124bn and $11.2bn in cash, Vertex's pain program needs further trials to overcome high placebo effects in Lumbosacral Radiculopathy. While Vertex's diversification is commendable, investors should wait for a few quarters of revenue from the pain program before making investment decisions. Read the full article on Seeking AlphaSeeking Alpha • Mar 06
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Summary Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals. The company’s 2024 performance was solid, with TRIKAFTA/KAFTRIO generating >$10bn revenues, and 2025 guidance suggesting continued growth despite some challenges. Vertex's diversification efforts include the approval of pain therapy JOURNAVX and gene therapy Casgevy, with potential multi-billion-dollar revenue contributions from these and other pipeline drugs. Despite potential headwinds, Vertex's strong cash position and promising pipeline support a “Buy” rating for VRTX stock, with expectations of further long-term growth and multiple blockbuster drugs. Read the full article on Seeking AlphaSeeking Alpha • Jan 31
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Summary JOURNAVX, a non-opioid analgesic, shows significant promise in treating pain with a superior safety profile, addressing a critical unmet need compared to opioids with FDA approval just announced. Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December. Vertex's valuation appears high due to recent expenses, but analysts expect substantial earnings growth in 2025 as acquisition and clinical expenses subside. With multiple ongoing clinical trials and a robust pipeline, Vertex is poised to exceed conservative analyst revenue projections, making the stock a STRONG BUY with a 12-month price of $550/share. Read the full article on Seeking AlphaSeeking Alpha • Jan 14
Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine
Summary I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is under investigation as a pain relief medication. In that earlier post on this drug, it had shown some very interesting (though modest) activity in post-surgical patients, albeit with some questions about its efficacy relative to Vicodin standard-of-care. Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain. Just before the holiday break, Vertex reported on another of these trials with suzetrigine in sciatica patients. Read the full article on Seeking AlphaSeeking Alpha • Dec 31
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Summary Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the cystic fibrosis (CF) drug market, including recent FDA approval for Alyftrek, ensures strong revenue and market expansion. The company's pipeline diversification, targeting diabetic peripheral neuropathy, IgA nephropathy, type 1 diabetes, and gene editing, promises long-term growth. Despite high valuation risks, VRTX's innovative CF treatments and diversified pipeline make it a compelling long-term investment opportunity. Read the full article on Seeking AlphaSeeking Alpha • Dec 11
Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
Summary I'm updating my recent “Buy” thesis on Vertex Pharmaceuticals Incorporated — spoiler alert, I am as bullish, if not more so, than I was back in September, despite a recent sell-off. Vertex's CF franchise remains robust, with TRIKAFTA generating $2.77bn in Q3 revenues and the upcoming Vanzacaftor triple therapy expected to drive further growth. Casgevy, a CRISPR-based therapy for Sickle Cell Disease and TDT, shows promising commercial potential, with multi-billion-dollar peak revenue projections and expanding global approvals. Upcoming catalysts include potential approvals for Vanzacaftor and Suzetrigine in January 2025, with Suzetrigine offering a non-opioid pain management solution. Vertex's long-term growth potential is strong, with promising pipelines in kidney disease, diabetes, and DMD, aiming for a $150bn valuation within 3–5 years. Read the full article on Seeking AlphaSeeking Alpha • Nov 25
Vertex Pharma: Why I Am Buying This Dip
Summary Vertex Pharmaceuticals reported strong Q3 earnings, yet the stock has pulled back, presenting a buying opportunity. The company’s robust pipeline, particularly Suzetrigine for acute pain and CASGEVY gene therapy, positions Vertex for significant growth. Vertex's financial health, with no traditional debt and substantial cash reserves, supports its aggressive push into new therapeutic areas and product launches. With three new products launching in 2025, Vertex is poised to exceed revenue estimates, making the current stock pullback an attractive entry point. Read the full article on Seeking AlphaSeeking Alpha • Nov 05
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Summary Vertex reported strong Q3 results driven by the growth of the cystic fibrosis franchise and raised the full-year revenue guidance range by $100 million at the mid-point. Casgevy finally generated commercial revenue in Q3 and Vertex continues to work in the background to get treatment centers up and running and patients treated. The VX-880 clinical program is progressing to the pivotal stage and povetacicept generated promising data in membranous nephropathy patients. Vertex Pharmaceuticals continues to deliver on both the commercial and clinical sides of the business, but the current valuation is already reflecting that. Read the full article on Seeking AlphaSeeking Alpha • Oct 18
Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Summary Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex treatment process and high costs, alongside competition from Bluebird Bio, make the launch challenging. Suzetrigine's potential in chronic pain, a large market with significant unmet needs, could drive substantial revenue if clinical data is positive. Vertex's strategic diversification beyond CF, with promising candidates like povetacicept for IgA nephropathy and cell therapies for T1D, may result in long-term growth. Read the full article on Seeking AlphaSeeking Alpha • Oct 10
Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)
Summary VRTX's core cystic fibrosis portfolio remains its top/ bottom-line driver, with elongated patent expiry for TRIKAFTA/KAFTRIO through 2037. Even so, the management is not resting on its laurels with numerous candidates in pipeline, along with new bolt-ons from recent acquisitions. These efforts have unfortunately triggered a deterioration in VRTX's balance sheet, with further acquisitions likely to trigger expensive debt reliance. At the same time, with most candidates in Clinical Phase 3 Trials, we are unlikely to see any top-line accretion in the near term. Given its relatively premium PEG non-GAAP ratio and the minimal upside potential, it may be better to observe VRTX's performance for a little longer. Read the full article on Seeking AlphaSeeking Alpha • Sep 15
Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug
Summary Vertex stock is significantly undervalued due to the underestimated potential of its pain treatment drug, VX-548, which could become a blockbuster. VX-548 has shown to be more effective than placebos and potentially more powerful than NSAIDs and ibuprofen in post-surgery pain relief. VX-548 appears to fill the therapeutic gap between NSAIDs and opioids. Read the full article on Seeking AlphaSeeking Alpha • Sep 05
Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Summary Vertex Pharmaceuticals, a leader in Cystic Fibrosis treatment, reported strong financials in Q2 but faces limited growth in CF due to high market penetration. Despite a GAAP net loss in Q2, Vertex remains highly profitable, with promising assets like Casgevy and Suzetrigine poised for future growth. Vertex's high valuation ratios suggest potential overvaluation, but its focused pipeline and blockbuster potential justify optimism for significant long-term revenue growth. Key risks include pricing pressure on CF drugs and competition in kidney disease markets, but Vertex's strategic focus could drive its valuation to $200bn by 2030. As such, I disagree with analysts who suggest Vertex have reached too high a valuation to continue to outperform the market. Read the full article on Seeking AlphaSeeking Alpha • Aug 02
Vertex Stock: Came For CF Drugs, Staying For Gene Therapy
Summary I am not a biotech expert, but I could not ignore the strength of Vertex's CF drug portfolio in 2022. The stock has almost doubled since then. While continuing to invest in innovative CF treatments, Vertex has been strategically expanding into gene therapy to treat other rare diseases. The company is expected to report approx. $85 million in gene therapy revenue this year from the commercialization of Casgevy to treat SCD and TDT. By forming new partnerships, expanding existing partnerships, and through technological advancements, Vertex will carve competitive advantages in the fast-growing gene therapy market in the future. Read the full article on Seeking Alpha주주 수익률
| VRTX | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | -0.007% | 1.3% | 2.2% |
| 1Y | -2.2% | 42.0% | 31.1% |
수익률 대 산업: VRTX은 지난 1년 동안 42%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: VRTX은 지난 1년 동안 31.1%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| VRTX volatility | |
|---|---|
| VRTX Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: VRTX는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: VRTX의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1989 | 6,400 | Reshma Kewalramani | www.vrtx.com |
버텍스 파마슈티컬스는 미국, 유럽 및 전 세계에서 생명공학 회사로 운영되고 있습니다. 이 회사는 낭포성 섬유증(CF), 겸상 적혈구 질환(SCD), 수혈 의존성 베타 지중해빈혈(TDT), 급성 통증 등 특수 시장에 중점을 두고 중증 질환 환자를 위한 혁신적 의약품을 제공합니다. 2세 이상의 F508del 변이가 하나 이상 있는 CF 환자를 위한 트리카프타/카프트리오, 6세 이상의 CF 환자를 위한 알리프트렉, 6세 이상의 CF 환자 치료를 위한 심데코/심메비, 1년 이상의 CF 환자 치료를 위한 오캄비, 1개월 이상의 CF 환자를 위한 칼리데코, 이바카프토를 판매하고 있다.
Vertex Pharmaceuticals Incorporated 기초 지표 요약
| VRTX 기초 통계 | |
|---|---|
| 시가총액 | US$109.09b |
| 순이익 (TTM) | US$4.34b |
| 매출 (TTM) | US$12.22b |
25.1x
주가수익비율(P/E)8.9x
주가매출비율(P/S)VRTX는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| VRTX 손익계산서 (TTM) | |
|---|---|
| 매출 | US$12.22b |
| 매출원가 | US$5.57b |
| 총이익 | US$6.65b |
| 기타 비용 | US$2.31b |
| 순이익 | US$4.34b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 17.09 |
| 총이익률 | 54.39% |
| 순이익률 | 35.51% |
| 부채/자본 비율 | 0% |
VRTX의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/11 13:25 |
| 종가 | 2026/05/08 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Vertex Pharmaceuticals Incorporated는 58명의 분석가가 다루고 있습니다. 이 중 29명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| Eliana Merle | Barclays |